NCT07089199View on ClinicalTrials.gov

Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer(TitAN) : A Prospective, Single-Arm, Phase II Study

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

July 25, 2025

Primary Completion Date

July 10, 2026

Study Completion Date

July 10, 2028

Conditions
NSCLCTislelizumabAnlotinibNab-paclitaxel
Interventions
DRUG

neoadjuvant therapy

tislelizumab （200mg，iv, q3w） + Anlotinib （10mg, orally, D1-14, q3w）+nab-paclitaxel（260mg/m2，q3w）3-4cycle

PROCEDURE

Surgery

Surgery should be performed 4 to 6 weeks after the last neoadjuvant therapy (at least 4 weeks after the end of anlotinib treatment).

DRUG

Adjuvant therapy

Tislelizumab: 200mg, iv, Q3W, 1year at most(including preoperative treatment medication, a total of 17 cycles).

All Listed Sponsors
lead

Qilu Hospital of Shandong University

OTHER